Arseniy Lavrov

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri, Francesco Muntoni, Giovanni Baranello et al. · The Lancet Neurology · 2021 · 256 citations

Medicine, Neurology, Neuroscience +12

Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial

Vincent Meininger, Pierre-François Pradat, Andrea M. Corse et al. · PLoS ONE · 2014 · 87 citations · Full text

Pharmacy, Neurology, Pharmacology +17

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Vincent Meininger, Angela Genge, Leonard H van den Berg et al. · The Lancet Neurology · 2017 · 85 citations · Full text

Life Sciences, Neurology, Neuroscience +10

Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study

Luis Garcia‐Gancedo, Madeline L Kelly, Arseniy Lavrov et al. · JMIR mhealth and uhealth · 2019 · 55 citations · Full text

Medicine, Health Informatics, Neurology +17

A 24‐week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease

Gareth Maher‐Edwards, Jeni De'Ath, Carly Barnett et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2015 · 53 citations · Full text

Medicine, Neurology, Pharmacology +17